Why the study?
Do hemostatic biomarker levels differ between patients with DVT and PE compared to those with DVT alone?
Do hemostatic biomarker levels differ between patients with DVT and PE compared to those with DVT alone?
Elevated levels of TAT, APC-PCI complex, PAI-1, and vWf may serve as sensitive indicators for the presence and risk of pulmonary embolism in patients with deep vein thrombosis.
Answers are grounded in this paper and cite their sources.
Higher APC-PCI, PAI-1, and vWf levels were associated with PE in DVT; hypothesis-generating and requires prospective validation before clinical use.
We investigated hemostatic abnormalities in 37 patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) (PE patients) and in 40 patients with DVT without PE (DVT patients). Plasma fibrinogen, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex, fibrin-D-dimer, activated protein C (APC)-protein C inhibitor (PCI) complex, von Willebrand factor (vWf), tissue plasminogen activator (t-PA), PA inhibitor-I (PAI-1), and thrombomodulin levels in both PE and DVT patients were significantly increased compared with normal volunteers. Plasma APC-PCI complex, PAI-1, and vWf levels in PE patients were significantly higher than those in DVT patients without PE. These findings indicate that PE patients are more hypercoagulable and hypofibrinolytic than DVT patients. Plasma TAT, APC-PCI complex, PAI-1, and vWf levels were the most sensitive indicators for PE. In these patients, increases in TAT and APC-PCI complex suggest DVT and increased PAI-1 and vWf suggest the risk of onset of PE.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: